在针对侵袭性三阴性乳腺癌的临床前研究中,Telomir Pharmaceuticals公司研发的候选药物Telomir-1展现出令人瞩目的抗肿瘤活性。实验数据显示,该药物能显著减缓肿瘤的生长速度,并有效抑制癌细胞的远端转移。
在针对侵袭性三阴性乳腺癌的临床前研究中,Telomir Pharmaceuticals公司研发的候选药物Telomir-1展现出令人瞩目的抗肿瘤活性。实验数据显示,该药物能显著减缓肿瘤的生长速度,并有效抑制癌细胞的远端转移。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.